Back to search

University of Patras

Αναδρομική μελέτη για τον καθορισμό ομάδας φαρμακογονιδιωματικών βιοδεικτών με σκοπό τον προσδιορισμό της δοσολογίας της τακρολίμης για την εξατομίκευση της θεραπείας μεταμοσχευμένων ασθενών

Abstract

dc:description

Tacrolimus is a cornerstone calcineurin inhibitor in immunosuppressive therapy following kidney transplantation, due to its high efficacy in preventing acute rejection and improving long-term graft survival. However, its clinical use is complicated by a narrow therapeutic window and pronounced pharmacokinetic variability, making dose optimization particularly challenging. Initial dosing is empirically based on body weight and subsequently adjusted through therapeutic drug monitoring of blood concentrations. This approach often results in under- or overexposure, especially during the early post-transplant period, thereby increasing the risk of acute rejection or drug-related toxicity, such as nephrotoxicity. Tacrolimus is primarily metabolized by the CYP3A4 and CYP3A5 enzymes. Genetic polymorphisms in the CYP3A5 significantly influence dose requirements, with CYP3A5 expressers requiring higher doses than non-expressers. Although current clinical guidelines recommend CYP3A5 genotyping, its clinical benefit remains uncertain. In addition, genetic variants in CYP3A4 and ABCB1 genes may further contribute to pharmacokinetic variability, although available evidence is limited. In this retrospective study, we evaluated the impact of combined CYP3A phenotypes on tacrolimus dose requirements and drug exposure in 94 Greek kidney transplant recipients, from treatment initiation up to one year post-transplantation. Patients were classified into four phenotypic groups based on the combined functional effects of CYP3A4 and CYP3A5. Moreover, the influence of transplant type, sex, age, and ABCB1 haplotypes on tacrolimus pharmacokinetics was evaluated. CYP3A5 expressers with increased CYP3A4 activity consistently exhibited lower dose-adjusted tacrolimus concentrations, indicating faster drug metabolism and higher dose requirements throughout the first post-transplant year. In contrast, no statistically significant effect of ABCB1 genetic variants on tacrolimus pharmacokinetics was observed. Recipients of kidneys from living donors required lower dose requirements during the first month after kidney transplantation, whereas sex and age did not appear to substantially affect therapeutic response. In conclusion, stratifying patients according to combined CYP3A pharmacogenomic phenotypes may represent a useful approach for tacrolimus dose optimization and improved immunosuppressive treatment in kidney transplantation.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tsironi, Anna
  • Τσιρώνη, Άννα

Subjects

dc:subject × 23

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/60713

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tsironi, Anna; Τσιρώνη, Άννα. Αναδρομική μελέτη για τον καθορισμό ομάδας φαρμακογονιδιωματικών βιοδεικτών με σκοπό τον προσδιορισμό της δοσολογίας της τακρολίμης για την εξατομίκευση της θεραπείας μεταμοσχευμένων ασθενών. University of Patras, 2025. http://hdl.handle.net/10442/hedi/60713